We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

301 hedge funds and large institutions have $799M invested in Iovance Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 100 increasing their positions, 93 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more call options, than puts

Call options by funds: $8.21M | Put options by funds: $6.57M

8% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 93

4% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 54

0% more funds holding

Funds holding: 301 → 301 (0)

6.13% less ownership

Funds ownership: 79.26% → 73.13% (-6.1%)

55% less capital invested

Capital invested by funds: $1.79B → $799M (-$989M)

71% less funds holding in top 10

Funds holding in top 10: 7 → 2 (-5)

Holders
301
Holders Change
–
Holders Change %
0%
% of All Funds
4.04%
Holding in Top 10
2
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-71.43%
% of All Funds
0.03%
New
56
Increased
100
Reduced
93
Closed
54
Calls
$8.21M
Puts
$6.57M
Net Calls
+$1.64M
Net Calls Change
+$9.18M

Top Buyers

Rank Fund Capital Flow
1
ICM
Invenomic Capital Management
Massachusetts
+$28.3M
2
LFCM
Long Focus Capital Management
Puerto Rico
+$21.2M
3
UBS AM
UBS AM
Illinois
+$20M
4
Renaissance Technologies
Renaissance Technologies
New York
+$18.1M
5
Bank of America
Bank of America
North Carolina
+$11.7M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$48.5M
2
ACA
Avoro Capital Advisors
New York
-$25.9M
3
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$20.1M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$13.5M
5
Man Group
Man Group
United Kingdom
-$12.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
NICM
301
Neo Ivy Capital Management
New York
– -$3.35M -453,138 Closed
CCM
302
Cinctive Capital Management
New York
– -$2.44M -329,204 Closed
PAM
303
Panagora Asset Management
Massachusetts
– -$1.59M -214,997 Closed
UOC
304
UBS O'Connor
Illinois
– -$1.11M -149,913 Closed
LCM
305
Landscape Capital Management
New Jersey
– -$791K -106,884 Closed
GLA
306
Great Lakes Advisors
Illinois
– -$772K -104,322 Closed
HSA
307
Hussman Strategic Advisors
Maryland
– -$622K -84,000 Closed
SAM
308
Sectoral Asset Management
Quebec, Canada
– -$603K -81,500 Closed
FCM
309
Fieldview Capital Management
Michigan
– -$551K -74,425 Closed
Jennison Associates
310
Jennison Associates
New York
– -$493K -66,568 Closed
SSA
311
Schonfeld Strategic Advisors
New York
– -$480K -64,850 Closed
VF
312
Virtu Financial
New York
– -$468K -63,276 Closed
SI
313
Shaker Investments
Ohio
– -$430K -58,085 Closed
KCM
314
Kennondale Capital Management
Virginia
– -$390K -52,769 Closed
Rockefeller Capital Management
315
Rockefeller Capital Management
New York
– -$343K -46,417 Closed
VEA
316
Virtus ETF Advisers
New York
– -$325K -43,927 Closed
CM
317
Caption Management
Oklahoma
– -$285K -38,500 Closed
Walleye Capital
318
Walleye Capital
New York
– -$261K -35,235 Closed
EAM
319
Erste Asset Management
Austria
– -$251K -34,000 Closed
LSA
320
Leonteq Securities AG
Switzerland
– -$150K -29,000 Closed
CC
321
Centiva Capital
New York
– -$202K -27,312 Closed
CIC
322
Carnegie Investment Counsel
Ohio
– -$200K -27,000 Closed
Nomura Holdings
323
Nomura Holdings
Japan
– -$196K -26,500 Closed
HT
324
Headlands Technologies
Illinois
– -$190K -25,725 Closed
CFD
325
Creative Financial Designs
Indiana
– -$172K -23,190 Closed
11 12
13
14 15

IOVA Hedge Fund Activity: Q1 2025 in Review

301 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2025, worth a combined $799M — down 55% from $1.79B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new IOVA positions and 54 closed out — a net gain of 2 holders — while 100 added to existing stakes and 93 trimmed.

The largest buyer was Invenomic Capital Management, opening a new position worth an estimated $28.3M. The largest seller was Perceptive Advisors, cutting an estimated $48.5M.

  • 301 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2025, unchanged from Q4 2024.
  • Funds reported $799M of Iovance Biotherapeutics stock for Q1 2025, down 55% quarter-over-quarter.
  • 56 funds opened new Iovance Biotherapeutics positions in Q1 2025 and 54 closed out, a net change of +2 holders.
  • The largest Iovance Biotherapeutics buyer in Q1 2025 was Invenomic Capital Management, an estimated $28.3M added.
  • The largest Iovance Biotherapeutics seller in Q1 2025 was Perceptive Advisors, an estimated $48.5M sold.

Based on aggregated 13F filings for Q1 2025.